Investing

0 1476
Amyris Inc AMRS Stock News

Amyris Inc (NASDAQ: AMRS) is having an incredibly strong day in the market today, and for good reason. The company announced that Q1 sales broke records. As a result, an investor frenzy ensued, leading to gains in the value of the stock and prompting our partners at Trade Ideas to send the alert. At the moment (10:49), AMRS is trading at $0.62 per share after a gain of $0.04 per share (6.47%) thus far today.





AMRS Announces Record Q1 Sales

As mentioned above, Amyris is having an incredibly strong day in the market today after announcing that Q1 sales broke records. The record was broken for Biossance brand sales. Not only is the brand delivering high-growth, but it is also expected to drive much better than expected 2017 results. In fact, Biossance Squalane + Peptide Eye Gell is currently the $1 selling eye product at SEPHORA.com, and the product continues to gain top reviews from leading industry publications. In a statement, John Melo, President and CEO at AMRS, had the following to offer:




We are excited by the growing contribution Biossance is making to our personal care business, and the robust growth we are experiencing in our nutrition business… We are off to a great start for the year driving growth across our business while pursuing strategic opportunities to improve our financial and competitive position as a leading company in our sector.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AMRS. In particular, we’ll be watching the continued growth of eye care products. Also, last year, the company closed several significant contracts that will likely lead to more products and revenue throughout the year. We’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the news before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikipedia]

0 1499
Rexahn Pharmaceuticals, Inc. RNN Stock News

Rexahn Pharmaceuticals, Inc. (NYSEMKT: RNN) is having an overwhelmingly rough day in the market today, and for good reason. The company announced that it would be moving forward with a reverse stock split, leading to fear among investors and declines in the stock. As is usually the case, our partners at Trade Ideas were the first to inform us of the declines. At the moment (10:36), RNN is trading at $0.51 per share after a loss of $0.10 per share (16.54%) thus far today.





RNN To Move Forward With Reverse Split

As mentioned above, Rexahn Pharmaceuticals is having a rough day in the market today after announcing that it would be moving forward with a reverse stock split. The split will be a 1 for 10 split. It was announced that the reverse split will become effective on May 5th.




While this is only an aesthetic change, it is a concern among investors. Ultimately, reverse splits are generally used to maintain listings on the market when the company sees no other way to improve the price of the stock. As a result, reverse splits, like the one we’re going to see from RNN lead to fear among investors.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on RNN. In particular, we’re interested in the reactions of investors as the reverse split moves forward. We’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Xilinx, Inc. XLNX Stock News

Xilinx, Inc. (NASDAQ: XLNX) is having a pretty strong day in the market today, and for good reason. Renewed takeover speculation is causing excitement among investors who are pushing the stock upward. Of course, our partners at Trade Ideas were the first to inform us of the gains. At the moment (10:10), XLNX is trading at $56.07 per share after a gain of $0.97 per share or 1.76% thus far today.





XLNX Gains On Takeover Speculation

As mentioned above, Xilinx is having a strong day in the market today as takeover speculation starts to make its rounds again. The idea here is that Qualcomm (QCOM) is interested in taking the company over. However, there’s no assurance from either side of the coin that this is going to happen, nor a suggested price.




The truth is that speculative trades and investments are incredibly high risk. While this may be creating a bit of an opportunity, XLNX could fall just as quickly as it rose. So, if you’re going to trade on this news, make sure that you trade with caution.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on both XLNX and QCOM. In particular, we’re interested in learning if there is any validity to the speculation. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Shopify Inc (US) SHOP Stock News

Shopify Inc (US) (NYSE: SHOP) was off to a rough day, trading in the red for the first 20 minutes or so. However, minutes ago, the stock started to spike in a big way as a rumor started to make the rounds. Of course, this prompted our partners at Trade Ideas to alert us to the gains. At the moment (9:56), SHOP is trading at $70.50 per share after a gain of $1.25 per share (1.81%) thus far today.





SHOP Gains On Takeover Rumors

As mentioned above, Shopify is having an overwhelmingly strong start to the trading session this morning after rumors started to break. The rumor is that the company will soon be taken over. However, the rumor is overwhelmingly vague. It doesn’t suggest who the buyer might be or at what price.




The truth is that we see these types of rumors in the market all the time. However, very few of them prove to be valid. In this particular case, we believe that the rumor lacks validity. While SHOP may be a good takeover target for someone, the rumor is incredibly vague and screams FALSE to us.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching for Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SHOP. In particular, we’re interested in following the potential takeover. While we don’t believe it’s going to happen, the truth is that anything can happen in the market. We’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 515
Nexvet Biopharma plc NVET Stock News

Nexvet Biopharma plc (NASDAQ: NVET) is having an overwhelmingly strong day in the market today, and for good reason. The company announced that it has received a takeover offer. As a result, an investor frenzy ensued, leading to massive gains and prompting our partners at Trade Ideas to alert us to the movement. At the moment (9:37), NVET is trading at $6.65 per share after a gain of $2.60 per share or 64.20% thus far today.





ZTS Makes A Bid For NVET

As mentioned above, Nexvet is having an overwhelmingly strong day in the market today after the company announced that it has received an acquisition bid. The bid came from Zoetis (ZTS), who offered the company $6.72 per share or about $85 million for the acquisition. That represents a 66% premium over yesterday’s close. It is expected that NVET will indeed take the offer and that the deal will close in the second half.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching NVET and ZTS incredibly closely. In particular, we’re interested in watching to see if the deal for Zoetis to acquire Nexvet Biopharma actually takes place. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Pixabay]

0 595
Celsion Corporation CLSN Stock News

Celsion Corporation (NASDAQ: CLSN) is having an overwhelmingly strong day in the market today, and for good reason. The company released positive clinical data, causing excitement among investors and pushing the stock upward. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:24), CLSN is trading at $0.36 er share after a gain of $0.06 per share or 20.57% thus far today.





CLSN Releases Positive Clinical Data

As mentioned above, Celsion Corporation is having a strong time in the market today after releasing positive clinical data. The data surrounded ThermoDox(R) as a way to increase concentrations of Doxorubicin accumulation and distribution within the bladder wall. According to the release, the data shows that this is exactly what’s happening. In a statement, Dr. Bradford Wood, MD, Director at the NIH Center for Interventional Oncology and Chief of the NIH Clinical Center Intervention Radiology had the following to offer…




The incomplete response of bladder tumors to intravesical drugs, like doxorubicin and mitomycin C, has been attributed in part to inadequate drug delivery and poor penetration across the urothelium resulting in sub-therapeutic drug concentrations in the bladder wall… To address this limitation, one promising strategy to enhance the permeability of the bladder wall to improve the efficacy of intravesical chemotherapy is the use of hyperthermia to stimulate the release of chemotherapeutic agents from thermosensitive nanocarriers for patients who have failed standard first line therapy for bladder cancer.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CLSN. In particular, we’re interested in following the continued work with regard to ThermoDox(R) as the data that was released today looks overwhelmingly promising. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikimedia]

Applied Optoelectronics Inc AAOI Stock News

Applied Optoelectronics Inc (NASDAQ: AAOI) is having an overwhelmingly strong day in the market today, and for good reason. The company released preliminary Q1 results that beat expectations. As a result, investors went into a frenzy, pushing the stock upward and prompting our partners at Trade Ideas to alert us of the movement. At the moment (9:05), AAOI is trading at $50.21 per share after a gain of $9.39 per share or 23.00% thus far today.





AAOI Releases Preliminary Q1 Results

As mentioned above, Applied Optoelectronics is having an incredibly strong time in the pre-market hours after releasing strong preliminary Q1 results. The unaudited results for the first quarter, which ended on March 31, 2017, are as follows…




  • Revenue – Approximately 96.2 million.
  • GAAP and non-GAAP Gross Margin – Between 42.5% and 42.9%.
  • GAAP Net Income – Between $18 million and $18.4 million.
  • GAAP Fully Diluted EPS – Between $0.91 and $0.94

In a statement, Dr. Thompson Lin, Founder, President, and CEO at AAOI, had the following to offer…

We delivered another strong quarter with our top and bottom-line results expected to exceed our guidance… Our results were driven by continued robust demand for our market-leading datacenter products and solid execution. We are pleased with our momentum and look forward to sharing the additional details of our first quarter performance on our conference call in May.”

Stop Wasting Your Time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AAOI. In particular, we’re interested in learning more about the company’s growth on the conference call next month. Nonetheless, we’ll continue to watch the news closely and bring it to you as it breaks!

Want The News Faster?

Get the scoop before we even have time to write the full story at the CNA Finance News Desk!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Aehr Test Systems AEHR Stock News

Aehr Test Systems (NASDAQ: AEHR) is having an overwhelmingly strong start to the trading session this morning after announcing the pricing of a public offering. Investors liked the price, sending the stock upward and prompting our partners at Trade Ideas to alert us of the movement. At the moment (8:44), AEHR is trading at $4.30 per share after a gain of $0.26 per share or 6.44% thus far today.





AEHR Prices Secondary Public Offering

As mentioned above, AEHR Test Systems is having an overwhelmingly strong day in the market today after announcing the pricing of a previously approved public offering. The company intends to offer 3,846,154 shares of common stock for sale to the public at a price of $3.90 per share. The company has also granted the underwriter a 30-day option to purchase an additional 576,923 shares of common stock at the offering price to cover over-allotments. It is expected that the offering will close on April 19th, but it is subject to customary closing conditions.




What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AEHR. In particular, we’re interested to see how quickly this offering is filled as well as watching the company through the use of that money toward growth. Nonetheless, we’ll continue to follow the news closely and bring it to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Pixabay]

0 312
Ocera Therapeutics Inc OCRX Stock News

Ocera Therapeutics Inc (NASDAQ: OCRX)

Ocera Therapeutics is having an overwhelmingly strong time in the pre-market hours today, and for good reason. The company announced the presentation of key clinical data, exciting investors and leading to incredible gains on the stock. Of course, our partners at Trade Ideas were the first to inform us of the gains. At the moment (8:13), OCRX is trading at $1.69 per share after a gain of $0.50 per share or 42.02% thus far today.





OCRX To Present Clinical Data

As mentioned above, OCRX is having an incredible morning in the market this morning after the company announced that it will be presenting clinical data. The data will be presented at The International Liver Congress(TM) 2017. the data will be coming from the study of omithine phenylacetate. The study that the data came from investigated the effect of OCR-002 in a NAFLD rat model . The rat models showed a significant reduction in the progress of fibrosis compared to untreated NAFLD rats. The treatment also showed to reduce liver/body weight ratio, hepatic lipid content, and hepatic collagen. In a statement, Stan Bukofzer, M.D., CMO at OCRX had the following to offer…




We are again excited to see evidence of OCR-002’s ability to target ammonia in hyperammonemia-related indications that in turn drives clinical improvement… In our recently completed STOP-HE Phase 2b study in patients hospitalized with acute heptic encephalopathy (HE), OCR-002 demonstrated a highly statistically significant correlation between rapid reduction of neurotoxin ammonia, and improved in the neurocognitive symptoms of HE (p=0.0006). The preclinical study to be presented at EASL demonstrated the impact of OCR-002 in a NAFLD model and its corresponding ability to significantly reduce progression of fibrosis, adding to our belief that OCR-002 may have broad potential to treat ammonia-driven complications.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on OCRX. In particular, we’re watching the development of OCR-002. While the treatment is still in pre-clinical phase, it looks overwhelmingly promising. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we even have the time to write the story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikimedia]

0 338
IntelliPharmaCeutics International Inc. IPCI Stock News

IntelliPharmaCeutics International Inc. (NASDAQ: IPCI) is in the midst of a strong run in the market and for good reason. The company announced that it would be challenging a key patent case. As a result, investors are excited and the stock is running to highs. Of course, our partners at Trade Ideas were the first to alert us of the trends. At the moment (1:42), IPCI is trading at $2.09 per share after a gain of $0.04 per share or 1.95% thus far today.





IPCI To Challenge Patent Infringement Case

Recently, investors heard about a patent infringement case that the company faced with regard to Rexista. The case was filed by Purdue Pharma, stating that Rexista infringes upon their patent. However, minutes ago, IPCI announced that it intends to challenge the patent suit.




What We’ll be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on IPCI. In particular, we’re interested in finding out more about the patent suit and following it through to the end to see who wins. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

What The News Faster?

Check out the CNA Finance News Desk to get the scoop before we even have time to write the story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Flickr]

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 4557
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...